

KEYWORD INDEX, VOLUME 47

Note: Page numbers followed by “f” indicate figures, and “t” indicate tables.

A

A1, 253–254, 256, 259, 322–323

A-385358, 255

A-769662, 151, 152

A-804598, 41

A β 42, 55–58, 59–60, 61

Abraxane, 245

ABT-199, 257

ABT-263, 257–258

ABT-267, 341

ABT-737, 256, 256f, 257, 260–261

AC-201, 178

ACC. *See* Acetyl CoA carboxylase (ACC)

Acetyl CoA carboxylase (ACC), 144–145, 148–149, 152, 153, 181–182, 183–184

ACH-2928, 341–342

ACH-3102, 341–342

Acolbifene, 479

ACS. *See* Acute coronary syndromes (ACS)

Activated partial thromboplastin time (APTT), 129–130, 136

Active targeting, 247–248

Acute coronary syndromes (ACS), 15, 137, 138, 509–512, 527–528

Acyl CoA:diacylglycerol acyltransferase (DGAT), 183

ADC. *See* Antibody drug conjugate (ADC)

Adenomatosis polyposis coli (APC), 396–397

Adenosine monophosphate-activated protein kinase, 143

Adenosine triphosphate (ATP), 40, 143, 144, 147, 149, 153, 282–283, 285, 286–287, 320–321, 322–325, 414

Adiponectin receptor, 183–184

Advanced glycation end products (AGEs), 163–164, 166–167, 169, 172

ADX10059 (raseglurant), 80–81, 84

ADX48621 (dipraglurant), 80–81, 83

ADX71149 (JNJ40411813), 78, 78t

AF. *See* Atrial fibrillation (AF)

Afatinib, 424–425

AFQ056 (mavoglurant), 80–81, 83

AGEs. *See* Advanced glycation end products (AGEs)

Agonist, 43–44, 45, 46–47, 73, 78, 78t, 90, 92, 99–100, 178, 187–189, 196, 197–198, 201, 203, 210–211, 388, 407, 442, 443–445, 448, 449, 450–452, 451f, 503, 558–560

Ago-PAM, 450–452

AICAR, 145–146, 149–150, 152

Albuminuria, 162–163, 166–167

Alisporivir, 479

ALK. *See* Anaplastic lymphoma kinase (ALK)

Allosteric ligand, 454–455

Allosteric modulation, 386f, 443, 449–450, 451f

Alzheimer’s disease, 30, 38, 40, 44–45, 46, 48, 55–69, 89–90, 147, 271

AMG369, 200

Amidine derived inhibitors, 63–64

Amino terminal domain (ATD), 90–92, 95, 101

Amitifadine, 480

AMPK, 143–157, 181–182, 183–184

Amyloid, 55–56, 65, 551

Amyloid beta peptides, 55–56, 271

Amyloid plaques, 55–56, 271

Amyloid precursor protein, 55–56

Anamorelin, 480

Anaplastic lymphoma kinase (ALK), 281–293, 500–501, 524–527

Antagonist, 5–6, 7–8, 15–16, 18–21, 39, 40, 41, 45, 73, 78t, 79, 97, 99–101, 112–113, 161–162, 166, 172–173, 187, 196, 198–199, 214, 387–388, 443, 444–445, 502, 514–515

Antibody drug conjugate (ADC), 347–366

Anti-oxidant compounds, 165

Antithrombotic, 123–125, 135–136, 137, 502

Anxiety, 5–6, 71–72, 73–74, 78, 78t, 79, 80–82, 84

AP26113, 286
APC. *See* Adenomatosis polyposis coli (APC)
Apixaban (BMS-562247), 135–136
Apixaban (Eliquis), 121–141, 502, 509–512
Apogossypolone, 259
Apoptosis, 253–254
APPRAISE, 138
APTT. *See* Activated partial thromboplastin time (APTT)
Arbaclofen placarbil, 481
ARISTOTLE, 138, 511–512
Aryl-ureas, 323–325
ASP3026, 286
AT101, 258–260
ATD. *See* Amino terminal domain (ATD)
Atherosclerosis, 146, 160, 223–235, 381, 384–385, 389–390
ATP. *See* Adenosine triphosphate (ATP)
Atrial fibrillation (AF), 137, 138, 511–512, 528–529
Auristatin, 354–355, 357–358, 359*t*
Avatrombopag, 481
AVERROES, 138
AVL-292, 427
Axis inhibition protein 2 (AXIN2), 396–397, 400–401, 402–404

B

BACE, 61–63, 64–65
BACE1, 55–57, 56*f*, 61–62, 63–65
Bad, 253–254
BAF312, 197–198
Baicalein, 277
Baicalin, 277
Bak, 253–254, 258, 259, 260–262
Bardoxolone methyl, 550, 165
Bax, 253–254, 258, 259, 260–262
Bcl-B, 253–254, 256
Bcl-2 inhibitors, 257, 259–260, 261–263
Bcl-w, 253–254, 256, 257–258
Bcl-x_L, 253–255, 256, 256*f*, 257–263, 273
Bedaquiline, 482
Begacestat, 57–58
Beloraniab, 434
Benzamidine, 126*f*, 127–132
Berberine, 149
Beta agonists, 210–211, 487

β-catenin, 370, 393–409
β-catenin / CBP inhibitor, 405–407
β-catenin / TCF-LEF inhibitor, 405–407
Beta lactamase, 421
β-secretase, 55–56
β-secretase inhibitors, 56, 61–65
β-TrCP / β-catenin enhancer, 396–397, 404–405
BFF-122, 44
Bfl-1, 253–254
BH3, 253–255, 256, 256*f*, 262–263
BI-201335, 483
Bifunctional compounds, 209–221
BILF1, 383–384
Bim, 253–254, 256*f*
Bind-014, 250*t*
BMS-708163, 57–58
BMS-741672, 162, 173, 230
BMS-790052, 332–333, 333*f*, 334, 335*f*, 336–338, 485
Boceprevir, 331–332, 418–419, 501–502, 521–523, 553
Brain imaging, 105–119
Brain permeability, 107–110, 112–113
Breast tumor cells, 375, 428
Brequinar, 313
Brexiprazole, 483
Bruton's tyrosine kinase (BTK), 426–427
BTK. *See* Bruton's tyrosine kinase (BTK)

C

CALAA-01, 250*t*
Calicheamicin, 355–356, 357–363, 359*t*
Calmodulin-dependent protein kinase kinase, 144
CaMKK, 152, 153
Cancer, 147, 147*t*, 239–240, 243*f*, 246, 247, 249, 253–255, 256, 260, 263, 271–273, 277, 281–293, 347–366, 371, 374–375, 377, 384, 385–386, 389–390, 394, 398, 399, 417–418, 424, 428–429, 432–433, 434, 459–460, 523–524, 525–526, 537–538
Cancer stem cells (CSCs), 272–273, 374–375, 405–406
Canonical Wnt Signaling, 397, 399
Carbohydrate responsive element binding protein (ChREBP), 144–145

- Carbon nanotubes, 46–47, 246
Carfilzomib, 433
Casein Kinase 1- α enhancer, 404
Cathepsin B, 423, 430
CC-1065, 356–357
CCR2, 161–162, 166, 169–170, 172–173, 229–230
CCR5, 172–173, 229–230, 231, 443–444
[¹¹C]CURB, 113–114
CCX140, 230
CDK2, 459–460, 461, 462, 463–464, 464*t*, 465–467, 469–470
CDP-791, 250*t*
CE-224,535, 40
Ceftolozane sulfate, 484
Celgosivir, 312
Cell-cell-interaction, 372
Cell cycle, 258, 269–270, 271, 272–273, 460, 466–467
Cell differentiation, 269–270
Cell polarity, 370
CEP-28122, 289
CF-101, 484
CH5424802, 282–283, 286–287
Chemokine receptors, 47–49, 162, 229–230, 381, 384–385, 443–444
Chemokines, 44–45, 47–48, 162–163, 229–231, 381, 382–383, 382*f*, 384–385, 386*f*, 443–444, 445–446, 448
Chronic obstructive pulmonary disease (COPD), 16–17, 209–210
Class C GPCR, 443–444
Clinical trials, 548–563, 31–33, 40, 45–46, 59–60, 61, 63–64, 65, 78–79, 83–84, 94, 100–101, 129–130, 137, 138, 160, 162–163, 164, 170–171, 173, 180–181, 183, 185, 196–198, 203–204, 213, 225, 226, 227, 228–229, 230, 231, 240–241, 250*t*, 257, 258–259, 271, 272–273, 275–278, 284, 285, 286, 320–321, 336–338, 339–340, 358–363, 390, 407–408, 421, 426–427, 431–432, 434, 443, 460, 477, 478, 506, 511–512, 526–527, 528–529, 533–535, 536–537, 538–539, 541–542, 551–552, 553–554, 559–560
[¹¹C]MK-3168, 113–114
[¹¹C]MP-10, 110–112
CNS MPO, 109–110
Co-culture, 375
Compound-membrane interaction, 108–109
Constitutive activity, 187, 382, 383–385, 386–388, 389
COPD, 209–221, 228–229
Coumermycin, 320–321, 322–323
CP-101,606, 90–91, 94, 97, 100
Crizotinib, 283–284, 285, 286–288, 290–291, 500–501, 525–527
CS-0777, 197
CSCs. *See* Cancer stem cells (CSCs)
[¹¹C]-(S)-3-(2'-fluoro-4,5'-dihydrospiro [piperidine-4,7'-thieno-[2,3-c]pyran-1-yl)-2(2-fluorobenzyl)-N-methylpropanamide, 112–113
CTS-21166, 62
CTX-4430, 228–229
CX3CR1, 47–49
Cyclin A, 459–460, 461–462, 463–464, 464*t*, 465–467, 466*f*, 469–470
Cyclin-dependent kinase-5 (CDK5), 38, 187–189
Cyclin groove, 460–467
Cytosine-phospho-guanine (CpG) DNA, 46–47
- D**
DAA. *See* Direct acting antiviral (DAA)
Dabrafenib, 485
Daclatasvir, 337–340, 341–342, 485
Dacomitinib, 425–426
Daunorubicin, 243
Daunoxone, 243
2D cell culture, 368–369, 371, 373, 374–376
3D cell culture, 367–378
Deep vein thrombosis (DVT), 131–132, 137, 502, 509–512, 527–529
Delamanid, 485
Dendrimers, 246, 247–248, 249
Dengue virus, 295–317
Depression, 31, 40, 73–74, 80–81, 89–90, 93, 97, 100–101, 209–210, 369, 480, 503, 558–560
Diabetes, 26–27, 63–64, 160, 172, 173, 177–178, 179, 502–503, 512–513, 540–541

Diabetic complications, 162–163, 166–167
Diagnostic test, 284, 290–291
7 α ,25-dihydroxycholesterol, 384
Dimethyl arginine dimethylamino
 hydrolase-1, 422–423
Dipeptidyl peptidase IV (DPPIV) inhibitors,
 178
Direct acting antiviral (DAA), 339–340, 342
Disease modifying approach, 55–69
DNA Gyrase, 320–321, 322, 324, 328
Dovitinib, 486
Doxil, 243–244
Doxorubicin, 242, 243–244, 250*t*
DPC423, 129–130, 130*f*
DPC602, 130
Drug design, 4, 9–10, 138, 282–283,
 441–457, 509–511, 521–522, 557
Drug discovery, 3, 4, 5–6, 9–10, 15, 16–17,
 21–22, 23, 25–34, 38, 41–42, 71–72,
 79–84, 105–106, 300, 313–314, 328,
 331–332, 367–378, 405, 414, 417–418,
 434–435, 441–457, 459–460, 469
Drug penetration, 375
Drug resistance, 240–241, 285, 290–291,
 375, 547–548
Drug sensitivity, 375, 377
Dual pharmacology, 212–213
Duocarmycin, 357, 359*t*, 363
DVT. *See* Deep vein thrombosis (DVT)

E

EC-145, 486
ECM. *See* Extracellular matrix (ECM)
EGFR. *See* Epidermal growth factor
 receptor (EGFR)
Electrokinetic chromatography, 108–109
ELND006, 57–58
Elongation of very long chain fatty acids
 protein 6 (Elov6), 185
EML4-ALK, 281–282, 284, 286–288,
 290–291
Enobosarm, 487
Epidermal growth factor receptor (EGFR),
 414, 424–426, 525–526, 555–556
Epithelial mesenchymal transition, 500–501
EPR Effect, 240–241, 247
E protein, 299–300, 301–302, 311, 312
Eprotirome, 487

Epstein–Barr virus-induced receptor 2
 (EBI2), 383–384, 385–386, 388, 389
Eritoran tetrasodium, 45–46
EVT-101, 94, 97, 100–101
Extended RVR (eRVR), 337, 339,
 553–554
Extracellular matrix (ECM), 166–167,
 368–372

F

FAAH. *See* Fatty acid amide hydrolase
 (FAAH)
Factor Xa (FXa), 121–141, 419, 502,
 509–512, 527–529
Fatty acid amide hydrolase (FAAH), 110,
 113–115, 117–118, 419–420, 431–432
Fibroblast growth factor receptor (FGFR),
 428–429
Fibroblasts, 218, 301, 312, 374–375, 389,
 503–504, 535–536
Fingolimod, 196–199, 203–204
FISH, 284
[¹⁸F]JNJ4150417, 110–112
[¹⁸F]JNJ42259152, 110–112
Flat SAR, 444–445
[¹⁸F]MK-0911, 112–113
[¹⁸F]PF-9811, 114–115
Fractalkine (CX3CL1), 47–49, 384–385,
 387–388
Fragile X syndrome (FXS), 71–72, 80–81,
 83, 84
FTY720, 196
Functional selectivity, 210–211, 444,
 448–449, 455
Functional switch, 445–448, 454
Fusion inhibitor, 31–32, 302–303
FXa. *See* Factor Xa (FXa)
FXS. *See* Fragile X syndrome (FXS)

G

γ -secretase, 55–56, 268, 271, 272–273,
 274–275, 277–278
 γ -secretase inhibitors (GSI), 20–21, 56,
 57–58, 65, 271–273, 277–278
 γ -secretase modulators, 56
Ganetespib, 487
GCS. *See* Glucosylceramide synthase (GCS)
Genexol-PM, 250*t*

Genistein, 273–274
Ghrelin receptor, 561, 187, 188f, 388
GHSR1a, 187
Gilenya, 196–197
Glucose transporter 4 (Glut4), 181, 297
Glucosylceramide synthase (GCS), 185
GluN1, 89–90, 92
GluN2A, 89–103
GluN2B, 89–103
GluN2C, 89–103
GluN2D, 89–103
Glut4, 145, 181
Glutamate, 43–44, 71–73, 89–90, 99–100, 101, 448–449
Glycation, 163
Glycine, 89–90, 99, 461–462
Glycogen synthase kinase 3 β (GSK-3 β), 277, 396–397
Gossypol, 258–260
GPCRs. *See* G protein-coupled receptors (GPCRs)
GPR120, 186–187, 186f
G protein-coupled receptors (GPCRs), 13–14, 16–17, 71–72, 183–184, 186–187, 195, 210–211, 226–227, 379–392, 441–457, 514–515
GS-5885, 340
GS-7977, 339, 488
GSK1842799, 199
GSK2336805, 341
GSK682753A, 388
GSK1838705A, 290
GSK-3 β . *See* Glycogen synthase kinase 3 β (GSK-3 β)
GSM, 58, 59–60, 61, 65
Guanidine derived inhibitors, 63–64
GyrA, 320–321, 322
GyrB, 320–321, 322, 323–325

H

Hanging drop technique, 372–373
Hepatitis C virus (HCV), 300, 331–345, 376, 417–419, 479, 483, 485, 488, 495, 501–502, 521–523, 553–554
Hepatitis C, 418, 423, 478, 521–522, 553
Hepatitis C virus NS5b RNA polymerase, 423

Hepatitis C Virus NS3/4a Protease, 303, 418
Herpesviruses, 381, 389–390
HES1, 269–270, 271–272, 273, 274–275, 277
HEY1, 269, 274, 277
High throughput screening (HTS), 9–10, 74, 76, 77, 97–98, 99–100, 151, 181, 185, 198–199, 202–203, 262, 275–276, 286–287, 290, 300, 373, 377, 444–445, 469, 540–541
HMG-CoA reductase, 8–9, 144–145
HTS. *See* High throughput screening (HTS)
Human 20S proteasome, 433
Hypoxia, 148, 249, 371, 375, 394–395, 493

I

[¹²³I]ADAM, 116–117
[¹²³I] β -CIT, 116–117
Ibrutinib, 426–427
Ifenprodil, 90–92, 92f, 94, 95, 96, 98
Iferanserine, 488
[¹²³I]FP-CIT, 116–117
iGluR, 89–90
Immunohistochemistry (IHC), 284
[¹²³I]5I-A-85380, 116–117
Imeglimin, 178
Immunomodulatory, 49, 196
Immunosuppression, 45, 47–48
Indole 2,3-dioxygenase (IDO), 42–43
Infectivity, 376
Inflammation, 37–38, 42f, 42, 43–44, 49, 146, 160, 161–162, 164, 165, 167–168, 186–187, 189, 196, 223–224, 381, 382, 389–390, 417–418, 521–522
Inhalation, 213, 219
Inhaled glucocorticoid, 212
Insulin resistance, 146, 160, 177, 179, 181, 185, 189, 540–541
Insulin Sensitizer, 179, 183–184
Inverse agonist, 187, 388, 389, 514–515
Irreversible covalent enzyme inhibitors, 423–434
Isoquinoline derivatives, 388
Isoquinolinone derivatives, 388
IWR-1, 400–401

J

JH295, 428
JNJ-40929837, 228–229

K

KARPAS-299, 286–287, 288–289, 290
Ketamine, 77, 93–94, 100
Kinase, 144, 148, 152, 282–283, 285, 290, 459–460, 472, 557
KRP-203, 197
Kynurenine aminotransferase II (KAT II), 42*f*, 43–44
Kynurenine pathway, 41–44

L

LABA, 210–214
LAMA, 210–212, 213–214
Lapatinib, 371, 424, 426
LDK378, 286
Lead optimization, 127–128, 130*f*, 138, 202, 203, 231–232, 325, 446, 452
Lenvatinib, 488
Lesinurad, 489
Leukocyte adhesion, 169
Leukotriene, 15–16, 79, 226–229
Linker, 20, 214–215, 216–217, 218, 353–356, 357–358, 359*t*, 363, 403, 419–420, 523–524
Lipoplatin, 250*t*
Liposomes, 46–47, 108–109, 242–245, 249, 250*t*
Liver Kinase B1, 144
LKB1, 144, 147, 148, 152
LRP6 inhibitor, 399
LY354740 (eglumetad), 73, 79
LY404039 (talaglumetad), 73–74
LY2140023 (pomaglumetad), 73–74, 78, 78*t*
LY2300559, 78*t*, 79
LY2812223, 73–74
LY2979165, 73–74, 78, 78*t*
Lymphopenia, 196, 198–199, 200–201, 202, 203

M

MABA, 215
Macrophage, 37–38, 161–163, 166, 169–170, 172–173, 185–187, 225, 226, 241–242, 377, 380, 519

Macrophage migration inhibitory factor (MIF), 434
Macular edema (ME), 167, 196–197
Major depressive disorders, 71–72, 84, 100, 483, 503
Maraviroc, 231, 443–444
Matrigel, 372
Maytansinoid, 351–352, 353–354, 357–358, 359*t*
Mcl-1, 253–255, 256, 257–263
MCP-1, 161–162, 166, 169–170, 172–173, 379, 384–385
Medicinal chemistry strategy, 417, 442
Metabotropic glutamate receptor (mGluR), 71–72
Metformin, 143, 145–146, 148–149, 152, 177–192, 541–542
Methionine aminopeptidase 2 (METAP2), 434
2'-Methyl-7-deazaadenosine, 307
mGluR2, 71–88
mGluR2/3, 72–73, 78, 78*t*, 84
mGluR3, 72–74, 72*t*
mGluR5, 71–88
Microcarrier beads, 372
Microvascular complications, 160, 166–167, 173, 540–541
Migraine, 78*t*, 79, 84, 116–117
Mitosis, 428, 467–468
MK0608, 307
MK-0657, 94, 100–101
MK-801, 5–6, 93–94, 95, 97
Modulator, 55–69, 71–72, 74–78, 79–81, 89–103, 177–192, 383–384, 385–388, 389–390, 400, 441–457, 503, 544–545
MOMP, 253–254
Monoacylglycerol lipase (MGL), 432
Monoclonal antibody, 500–501, 503–504, 519, 523–524, 537–538
Montelukast, 229
MRZ-8676, 80
MSDC-0602, 178
Multicellular spheroids, 372–373
Muscarinic receptor, 210–211, 210*f*, 540–541
Muscarinic receptor antagonist, 210–211, 213–217

Mycobacterium tuberculosis, 319–320, 377
Myocet, 242, 243–244

N

Naloxegol, 489
Nanoparticles, 47, 240, 241–246, 247–251, 250*r*
Nanotechnology, 237–252
Naphthyridines, 325–327
NCI-H2228, 286–287, 289
Negative allosteric modulator (NAM), 71–72, 79–81, 442, 443
Nek2, 428
Nephropathy, 160, 162–167, 177
Neratinib, 424
Netupitant, 489
Neurite outgrowth, 369, 376–377
Neuroendocrine tumors, 269
Neuroinflammation, 35–53
Neuropathy, 100–101, 160, 171–173, 177, 504, 524–525, 551–552
Neurospheres, 376–377
Niclosamide, 275, 277, 399
NK105, 245
NMDA, 5, 20–21, 41–42, 89–103
Non-ATP competitive, 459–474
Non-druggable GPCR, 442
Non-specific binding, 98, 107–108
NOTCH, 56–58, 65, 267–280, 399
Novobiocin, 320–321, 322–324
Noxa, 253–254
NPM-ALK, 281, 283–284, 286–287, 288, 289
NS5A, 306, 331–345, 553
NSAIDs (non-steroidal anti-inflammatory drugs), 168, 399
NS4B, 299–300, 306
NS2B/NS3 protease, 303–306
NSCLC, 250*r*, 255, 257, 281–282, 284, 285, 287, 290–291, 424–426, 525–527
NS3 helicase, 306
NS5 methyltransferase, 295–317
NS5 polymerase, 307–309
NVP-TAE684, 282–283, 286, 287, 288–289, 290
NXL-104, 421

O

Obatoclax, 258
6-O-butanoylcastanospermine, 312
Oncogene, 269, 281–282, 284, 381, 383, 384–385, 525–526, 555
Oncology, 237–252, 263, 290–291, 350–351, 373, 374–375, 459–474
Opicapone, 490
ORF74, 380, 382–383, 386–387, 388
ORL-1, 110
Orthosteric agonist, 450
Ozenoxacin, 490

P

Paclitaxel, 245, 250*r*, 255, 256
Pain, 20, 38, 39, 40, 41, 45, 48, 80–81, 89–90, 96, 100–101, 113–114, 171, 172–173, 230, 419–420, 431–432, 508, 532–533, 536–537, 551–552, 556
Parkinson, 83
Parkinson's disease levodopa-induced dyskinesia (PD-LID), 71–72, 83
Passive targeting, 240–241, 247
PCP, 77, 78, 93–94, 97
PDE10a, 110–112
PDE4 inhibitor, 210*f*, 211–212, 213, 217, 218
Peptide, 5–7, 31–32, 58, 65, 112–113, 127, 172–173, 178, 183–184, 187, 226, 248, 256*f*, 271, 302–303, 357–358, 418, 420, 431, 449, 460–461, 462–464, 465–466, 468, 468*f*, 469–472, 509–511, 516–517, 527–528, 538–539, 540–541, 553
Perphenazine 4-aminobutyrate, 490
Personalized medicine, 23, 390, 455
Personalized therapy, 290–291
PET, 98, 105–119, 453–454
PET radionuclides, 106–108
PET tracer development, 105–106, 107–108, 109–110, 114–115
PF991, 197–198
PF-02341066, 283–284, 525–526
PF-4859989, 44
Phenylethanolamine, 90–91, 94, 95–98
Phosphodiesterase inhibitor, 164
Phospholipase, 210–211, 210*f*, 224–226, 380, 386–387, 443

Physicochemical properties, 109–110, 246, 283–284, 454
Pioglitazone, 146, 148–149, 178
Piperidinyl quinoline, 325–327
PKC- β (protein kinase C - β), 166–167, 171
PLK1, 459–460, 467–468, 469–472, 471*t*
PLK3, 469, 470–471, 471*t*
Polo box domain, 467–472
Polymer–drug conjugate, 244–245
Polymeric Nanoparticles, 244–245
Ponesimod, 197–198
Porcupine inhibitor, 397
Positive allosteric modulator (PAM), 74–78, 100, 442, 443–444, 450, 503, 544–545
Peroxisome proliferator-activated γ (PPAR γ), 65, 148–149, 178, 187–189
PPI-668, 341
Presenilin, 107–108
Probe dependency, 443, 448, 455
Prodrugs, 8–9, 73–74, 153, 161, 197, 198–199, 203–204, 226, 308, 356, 359*t*, 478, 503, 505–506, 514–515, 533–534
Prolongation of prothrombin time (PT), 134–135, 136
Prolyl oligopeptidase, 420
Protein phosphatase methylesterase-1, 432–433
Protein–protein interaction, 254–255, 414, 459–460, 461*f*, 462, 466–467, 472
Protein tyrosine phosphatase-1b (PTP-1b), 179
Psychotomimetic, 93
PT1, 153
Puma, 253–254
Pure PAM, 442, 450–452
P2X₄, 39–40
P2X₇, 39, 40–41
Pyrrolamides, 325

R

Radioligand, 41, 98, 453–454
RAGE (receptor for advanced glycation end products), 163, 169, 172
Rapid virological response, 337
Razaxaban (BMS-562389), 129–132, 133, 509–511

Razaxaban (DPC906), 129–132, 133, 509–511
RdRp polymerase, 299–300
Receptor occupancy, 113–114, 117–118, 453–454
REPLACE, 459–460, 461*f*, 462–464, 463*f*, 469–472
Resistance, 146, 160, 177, 179, 181, 185, 189, 240–241, 253–254, 256, 285, 290–291, 305–306, 320–321, 324, 325–326, 334–335, 337–338, 339–340, 341–342, 357–358, 375, 414, 422, 424–425, 531–532, 540–541
Resveratrol, 149, 275–276
Retinoblastoma binding protein 9, 422
Retinopathy, 160, 167–171, 177
Reversible covalent enzyme inhibitors, 417–423
RG7128, 308
RGH-896, 94, 98, 100–101
Ro 25-6981, 90–92, 92*f*, 94, 97
RO4917523, 83, 84
Rosiglitazone, 146, 148–149, 178, 187–189
Rotary wall vessel, 372–373
Reverse transcriptase-polymerase chain reaction (RT-PCR), 284
RVR, 337, 338, 341

S

Sabutoclax, 259
Salicylates, 161, 168
Sapacitabine, 491
SAR-302503, 491
SB-568859, 225
SBHA. *See* Suberoyl bishydroxamic acid (SBHA)
Schizophrenia, 38, 71–72, 73–74, 78, 78*t*, 84, 448–449, 490, 495
Semagacestat, 57, 65
Sequence homology, 72–73, 253–254, 381, 384–385, 389–390
Serine protease, 128–131, 135–136, 138, 299–300, 303, 416, 418–419, 509–511, 527–528, 553
S-ESBA, 44
Setipiprant, 491
Silent allosteric modulator, 442, 447–448

Small molecule inhibitors, 183, 255–263, 273–275, 282–283, 302, 303, 319–320, 322, 331–332, 332*f*, 393–409, 414, 465–466

S1P, 195, 196

S1P1, 193–207

S1P3, 196–197, 199–201, 202–203

SPECT, 98, 105–119

SPECT radionuclides, 106–107, 106*t*, 115–116, 117

Spheroids, 370, 371, 373, 374, 375, 376

Sphingosine, 195

Sphingosine-1-phosphate, 193–207

SREBP. *See* Sterol regulatory element-binding protein (SREBP)

Sterol regulatory element-binding protein (SREBP), 144–145, 181

Structure-activity relationship, 112–113, 353–354, 386–387, 401, 444–448, 460–461, 469–471

STX107, 83

Suberoyl bishydroxamic acid (SBHA), 276–277

Sustained viral response (SVR), 331–332, 337, 339–340, 342, 521–523, 553–554

SVR. *See* Sustained viral response (SVR)

T

TAK-242, 45–46

TAK-438, 492

TAK-875, 492

Tankyrase inhibitor, 400–404

Tarenflurbil, 58, 59, 65

Target controlled release, 248–249

Targeted covalent enzyme inhibitors, 411–439

Targeted therapy, 350–351, 557

Tasquinimod, 492

T-cell acute lymphoblastic leukemia (T-ALL), 269, 271, 272–273

[^{99m}Tc]TRODAT-1, 115–116

T2DM. *See* Type 2 diabetes mellitus (T2DM)

Telaprevir, 331–332, 339–340, 418, 501–502, 521–522, 552–554

TH-302, 493

Therapeutic, 3, 5–7, 27, 30, 32–33, 46, 48, 65, 71–73, 76, 83, 94, 96, 101, 136, 145,

146–147, 161, 162, 203–204, 210–213, 216–217, 219, 237–252, 258–259, 271, 273–274, 277, 303, 306, 307, 319–330, 332, 336, 354–355, 359*t*, 364, 374–377, 379–392, 396, 414, 442–443, 449, 459–460, 466–467, 480, 493, 500, 502–503, 509–511, 527–528, 538–539

Thermodox, 249, 250*t*

Thiazolidinedione (TZD), 30, 148–149, 178, 189

Thrombin, 124–125, 136, 419, 502, 509–511, 527–528

Tight junction proteins, 370

Tissue transglutaminase 2, 431

Toll-like receptor 4 (TLR4), 44–46

Toll-like receptor 9 (TLR9), 44–45, 46–47

Topoisomerases, 320–321, 321*f*, 325–326

Tozadenant, 493

Tractable SAR, 445

Transplant rejection, 384, 417

Traxoprodil, 90–91

Trelagliptin, 493

Tumor acidification, 375

Tumor-associated antigen, 351

Tumor microenvironment, 371, 375

Tumor suppressor, 147, 267–268, 269–270, 469

TW-37, 259–260

Type 2 diabetes, 159–175, 177–192, 230, 502–503, 540–542

Type 2 diabetes mellitus (T2DM), 143, 146, 148, 492, 493, 541–542

Type-II SH2-domain-containing inositol 5-phosphatase (SHIP2), 179

U

Ulimorelin, 494

Umeclidinium Bromide, 494

US28, 384–388, 389

V

Valproic acid, 276–277

Vaniprevir, 495

Venous thromboembolism (VTE), 137, 138, 502, 509–512, 527–529

Viral Nanoparticles, 246

VTE. *See* Venous thromboembolism (VTE)

VUF2274, [386–387](#)

VVP808, [178](#)

W

Withaferin A, [274](#)

Wnt pathway inhibitors, [402–404](#)

Wolff-Parkinson-White syndrome, [147](#)

WS010117, [149–150](#)

WYE304529 (GRN529), [80–81](#)

X

X-396, [287–288](#)

XALKORI, [283–284](#), [500–501](#), [525–527](#)

XAV939, [402](#)

X-ray, [4](#), [6–7](#), [8–9](#), [90–92](#), [126](#), [128–129](#),
[131–132](#), [135](#), [135f](#), [138](#), [256f](#),
[257–258](#), [290](#), [309](#), [310](#), [334](#), [401](#),
[402](#), [403](#), [434](#), [462–463](#), [509–511](#),
[546–547](#)

Z

Zafirlukast, [15–16](#), [18](#), [229](#)

Zicronapine, [495](#)

ZMP, [149–150](#)